Abstract
The ability to silence specific genes of choice consistently and efficiently has always been a major goal for scientists. The emerging field of RNA interference (RNAi), a process in which target mRNAs are degraded by small interfering RNA (siRNA), may indeed provide this long sought after tool. The importance of this technology has been highlighted recently by Science, which has voted the RNAi discoveries as the “ & ;Breakthrough of the Year” in 2002. Essentially, RNAi involves an initiation and an effector step whereby introduced dsRNA is digested into 19-21 duplex siRNA by cleavage with Dicer and siRNA binds to an RNA-induced silencing complex (RISC). Activation of RISC targets the homologous sequence (transcript) and results in the cleavage of mRNA. The models of this RNAi mechanism and its applications, derived from biochemical and genetic approaches, are described in this minireview. So far, RNAi has proven to be a useful technique for genomic studies in C.elegans, D.melanogaster and various plants, for example. The use of RNAi has also been invaluable in studies in which morphological and developmental variability between species was investigated. Targeted, sequence specific siRNAs that suppress or silence gene expression have the potential to be in great demand as tools for for the treatment of human disease. There have already been several studies that have utilized siRNA to inhibit HIV-1 infection and replication, for example. The expansion of RNAi for biomedical therapeutics seems inevitable. This minireview analytically summarizes the advantages and the current and future potential of RNAi technology whilst simultaneously investigating any shortfalls or difficulties. Importantly, in vitro and in vivo applications in the laboratory and in human disease models are also described.
Keywords: sirna, rnai, co-suppression, ptgs
Current Genomics
Title: Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA)
Volume: 4 Issue: 7
Author(s): Jim Apostolopoulos
Affiliation:
Keywords: sirna, rnai, co-suppression, ptgs
Abstract: The ability to silence specific genes of choice consistently and efficiently has always been a major goal for scientists. The emerging field of RNA interference (RNAi), a process in which target mRNAs are degraded by small interfering RNA (siRNA), may indeed provide this long sought after tool. The importance of this technology has been highlighted recently by Science, which has voted the RNAi discoveries as the “ & ;Breakthrough of the Year” in 2002. Essentially, RNAi involves an initiation and an effector step whereby introduced dsRNA is digested into 19-21 duplex siRNA by cleavage with Dicer and siRNA binds to an RNA-induced silencing complex (RISC). Activation of RISC targets the homologous sequence (transcript) and results in the cleavage of mRNA. The models of this RNAi mechanism and its applications, derived from biochemical and genetic approaches, are described in this minireview. So far, RNAi has proven to be a useful technique for genomic studies in C.elegans, D.melanogaster and various plants, for example. The use of RNAi has also been invaluable in studies in which morphological and developmental variability between species was investigated. Targeted, sequence specific siRNAs that suppress or silence gene expression have the potential to be in great demand as tools for for the treatment of human disease. There have already been several studies that have utilized siRNA to inhibit HIV-1 infection and replication, for example. The expansion of RNAi for biomedical therapeutics seems inevitable. This minireview analytically summarizes the advantages and the current and future potential of RNAi technology whilst simultaneously investigating any shortfalls or difficulties. Importantly, in vitro and in vivo applications in the laboratory and in human disease models are also described.
Export Options
About this article
Cite this article as:
Apostolopoulos Jim, Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA), Current Genomics 2003; 4 (7) . https://dx.doi.org/10.2174/1389202033490178
DOI https://dx.doi.org/10.2174/1389202033490178 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Icaritin and β-anhydroicaritin Mannich Base Derivatives and Their Cytotoxic Activities on Three Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design HLA Associations with Nasopharyngeal Carcinoma
Current Molecular Medicine Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Chemopreventive Properties of Indole-3-Carbinol, Diindolylmethane and Other Constituents of Cardamom Against Carcinogenesis
Recent Patents on Food, Nutrition & Agriculture Non-Traditional Drug Targets: High Risk, High Reward
Current Gene Therapy High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Insights into Antimicrobial Peptides from Spiders and Scorpions
Protein & Peptide Letters Image Fusion Based on Estimation Theory: Applied to PET/CT for Radiotherapy
Recent Patents on Medical Imaging Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Laminin and Collagen IV: Two Polypeptides as Marker of Dystocic Labor
Current Protein & Peptide Science